AMPLY Discovery, a Belfast-based AI drug discovery company, secured $1.75M in seed funding, led by Twin Path Ventures and others, to enhance medicine development. The company focuses on gene-silencing therapies for cancers like triple-negative breast cancer and developing nebulised treatments for drug-resistant lung infections. Founded by Dr. Ben Thomas and his team from Queen's University Belfast, AMPLY utilizes a computational platform built over a decade of research, integrating AI, Next Generation Sequencing, and Synthetic Biology to improve drug discovery and treatment efficacy for genetically variant diseases.
Ten years ago, I began combining financial modeling expertise with computational biology to create a drug discovery platform. Evolution has spent billions of years perfecting natural defence mechanisms, and now we're using AI to unlock this wisdom.
This isn't just professional for me; my father died from a drug-resistant infection our healthcare system couldn't treat. At Queen's, I built AMPLY to tackle deadly diseases differently, creating technology that will save lives when current treatments fail.
AMPLY Discovery is developing gene-silencing therapies for cancers like triple-negative breast cancer and acute myeloid leukaemia, and advancing preclinical drug discovery programmes for lung infections.
The company’s platform integrates AI, Next Generation Sequencing, and Synthetic Biology to develop treatments for diseases associated with genetic variation, identifying treatment targets and bio-printing molecules.
Collection
[
|
...
]